Protocol Ledger

NCT06103825 · Phase III · COMPLETED

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with O

Interventional Phase III clinical trial protocol NCT06103825 sponsored by Ignis Therapeutics (Suzhou) Limited in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-01 Enrollment: 204 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06103825
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)204 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06103825
Protocol FieldVerified Registry Value
NCT IdentifierNCT06103825
Consolidated Lead SponsorIgnis Therapeutics (Suzhou) Limited
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment204 participants (ACTUAL)
Registered Start Date2023-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI